Lenvatinib Breakthrough Designation, New Drug Applications for NSCLC, STS, and More

Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.

Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.

Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.

Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.

Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.